Paragon Bioservices Announces the Appointment of Robert Roche to its Board of Directors
Baltimore, MD, November 11, 2015/PR Newswire/ – Paragon Bioservices, a global leader in the manufacturing of biopharmaceuticals and vaccines, announced today the appointment of Robert Roche to the Company’s Board of Directors, effective October 27, 2015.
“We are very pleased that Bob is joining our Board,” commented Dr. Marco Chacon, Paragon’s Founder and CEO. “His extensive knowledge and experience in the pharmaceuticals industry in business strategy and operations will be greatly valued as we continue our growth. As a board member, Bob has also gained experience with companies going through extensive growth.”
Mr. Roche is the founding member of Robert Roche Associates LLC, a consulting firm providing guidance to the pharmaceutical and healthcare industries. He created this firm upon his retirement from Cephalon Inc., in February 2010. He joined Cephalon in January 1995 as the Vice President of Sales and Marketing and was named Executive Vice President, Worldwide Pharmaceutical Operations in 2005. Before joining Cephalon, Mr. Roche served as Director and Vice President, Worldwide Strategic Product Development, for SmithKline Beecham’s central nervous system and gastrointestinal products business. He also was managing director of SmithKline’s pharmaceutical operations in the Philippines. Prior to that, he held senior marketing positions in Canada and Spain and had product planning responsibilities for SmithKline in Latin America. Mr. Roche began his pharmaceutical career in 1982 with SmithKline & French as a U.S. pharmaceutical sales representative.
Mr. Roche is a member of the boards of directors of Aratana Therapeutics of Kansas City, KS, and Antares Pharmaceuticals of Ewing, NJ. He formerly served as a director of LiceCell, Inc., up until its acquisition in 2008, EKR Therapeutics, until its acquisition in 2012, Civitas Therapeutics of Chelsea, MA, and NuPathe, Inc., of Conshohocken, PA, until they were acquired in 2014. He also serves on the board of Bryn Mawr Hospital. He is a graduate of Colgate University and earned an MBA from The Wharton School at the University of Pennsylvania.
About Paragon Bioservices, Inc.
Paragon Bioservices is a private‐equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of biopharmaceuticals—including the production and purification of monoclonal antibodies, recombinant proteins, viral vectors and vaccines. The company provides research services, process development and cGMP manufacturing. Paragon’s cGMP facilities include microbial and mammalian suites, fill‐finish and fully‐segregated virus facilities.
Kevin Sly, SVP Marketing & Commercial Strategy
PH (410) 975‐4050